title: [Effects of hyperoxia regimes on the state of lipid peroxidation and hemostasis in patients with lesions of the central nervous system].
abstract: Lipid peroxidation and some parameters of hemostasis were studied during exposure to various hyperoxia schemes combined with heparin therapy before and after treatment in 124 patients aged 16 to 69 with CNS involvement which developed as a result of atherosclerosis and essential hypertension, 60 of whom presented with initial manifestations of cerebral circulation insufficiency (IMCCI), 33 with posthypoxic encephalopathies (PE), and 31 with ischemic stroke (IS). Hyperoxia mechanisms were differently directed in the studied groups of patients, this necessitating a differentiated approach to the choice of schemes of hyperbaric oxygenation. Use of a short course of hyperbaric oxygenation (up to 3 sessions at 1.2 to 1.25 atA) is recommended for patients with IMCCI and PE. For patients with IS in the acute period hyperbaric oxygenation at 1.4 atA is advisable combined with heparin therapy in doses of 150 to 300 U/kg b.w. a day.
authors.forename: V V
authors.initials: VV
authors.lastname: Shchukovskiĭ
authors.forename: G G
authors.initials: GG
authors.lastname: Zhdanov
authors.forename: O N
authors.initials: ON
authors.lastname: Voskresenskaia
authors.forename: O L
authors.initials: OL
authors.lastname: Kosiagina
authors.forename: O V
authors.initials: OV
authors.lastname: Belov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001927:Brain Diseases / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D006487:Hemostasis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D015227:Lipid Peroxidation; D008875:Middle Aged; D013997:Time Factors
chemical_list: D006493:Heparin
vernacular_title: Vliianie rezhimov giperoksii na sostoianie perekisnogo okisleniia lipidov i gemostaz u bol'nykh s porazheniiami tsentral'noĭ nervnoĭ sistemy.